drugset / Trial / NCT02232308

Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects

NCT02232308

RandomizedParallel-groupDouble-blindBasic science

Summary

To assess if oral nizatidine or lisinopril alone and in combination will increase heme oxygenase 1 (HO-1) protein concentration and activity compared to placebo in healthy subjects.

Timeline

Start
2014-07
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject LISINOPRIL ANHYDROUS Small molecule 10 mg Oral
Subject Nizatidine Small molecule 150 mg Oral

Indications